home / stock / bfra / bfra news

BFRA News and Press, Biofrontera AG From 10/10/19

Stock Information
Company Name: Biofrontera AG
Stock Symbol: BFRA
Market: NASDAQ
Menu
BFRA BFRA Quote BFRA Short BFRA News BFRA Articles BFRA Message Board
Get BFRA Alerts

News, Short Squeeze, Breakout and More Instantly...
BFRA - Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019

Leverkusen, Germany, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-group”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the third q...
BFRA - Biofrontera Files Label Extension for Ameluz® in EU to include Treatment of Actinic Keratosis on Extremities and Trunk/Neck

Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has filed a label extension for Ameluz ® with the European Medicines Agency (EMA) on August 2...

BFRA - Biofrontera to participate at the Lake Street Capital Markets 2019 Best Ideas Growth (BIG) Conference

Leverkusen, Germany, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be participating in the Lake Street Capital Markets 2019 Best Ideas Growth (BIG) Conference, h...

BFRA - Biofrontera: A Small European Biotech With Interesting Value Proposition

Biofrontera AG ( BFRA ) is a small-cap German pharmaceutical company cementing its place in the photodynamic therapy market. It has an approved product Ameluz that has been on the EU market since 2012 and the USA market since October 2016. Ameluz is a prescription medication to treat non-melan...
BFRA - Biofrontera AG (BFRA) CEO Hermann Lübbert on Q2 2019 Results - Earnings Call Transcript

Biofrontera AG (BFRA) Q2 2019 Earnings Conference Call August 27, 2019 08:00 ET Company Participants Pamela Keck - Investor Relations Hermann Lübbert - Chief Executive Officer Christoph Dünwald - Chief Commercial Officer Thomas Schaffer - Chief Financial Officer Co...

BFRA - Biofrontera shows robust growth during first six months of 2019

Leverkusen, Germany, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its results for the first six months ended June 30, 2019. At the same time, Biofronte...

BFRA - Biofrontera Announces Conference Call on August 27, 2019 to Discuss Half-year 2019 Financial Results

Leverkusen, Germany, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2019 on August 27, 2...
BFRA - Biofrontera provides update on Cutanea integration

Leverkusen, Germany, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, provides an update on the integration progress of Cutanea Life Scienc...

BFRA - Results of the voluntary partial tender offers

Leverkusen, Germany, July 24, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about the conclusion of the voluntary public partial tender offers of Maruho Deutschland Gmb...

BFRA - Annual General Meeting of Biofrontera AG: Biofrontera Management Board approved by large majority

Leverkusen, Germany, July 11, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the results of the Annual General Meeting held on 10 July 2019. The shareholders pre...
Previous 10 Next 10